Terms: = Leukemia AND ITK, PSCTK2, 3702, Q08881, ENSG00000113263, EMT, MGC126258, LYK, MGC126257 AND Treatment
113 results:
1. miR-26b-5p Affects the Progression of Acute Myeloid leukemia by Regulating the USP48-Mediated Wnt/β-Catenin Pathway.
Xie Y; Tan L; Wu K; Li D; Li C
Crit Rev Eukaryot Gene Expr; 2024; 34(4):33-44. PubMed ID: 38505871
[TBL] [Abstract] [Full Text] [Related]
2. Epithelial-Mesenchymal Transition in Acute leukemias.
Varisli L; Vlahopoulos S
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396852
[TBL] [Abstract] [Full Text] [Related]
3. PBX1 as a novel master regulator in cancer: Its regulation, molecular biology, and therapeutic applications.
Kao TW; Chen HH; Lin J; Wang TL; Shen YA
Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189085. PubMed ID: 38341110
[TBL] [Abstract] [Full Text] [Related]
4. Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer.
Zeng Z; Fu M; Hu Y; Wei Y; Wei X; Luo M
Mol Cancer; 2023 Oct; 22(1):172. PubMed ID: 37853437
[TBL] [Abstract] [Full Text] [Related]
5. Cordycepin improves sensitivity to temozolomide in glioblastoma cells by down-regulating MYC.
Zheng SX; Chen J; Zhuang BB; Zhang Q; Shi SS; Zhang GL
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16055-16067. PubMed ID: 37695389
[TBL] [Abstract] [Full Text] [Related]
6. Epigenetic deregulation of MLF1 drives intrahepatic cholangiocarcinoma progression through EGFR/AKT and Wnt/β-catenin signaling.
Tang Z; Yang Y; Chen W; Liang T
Hepatol Commun; 2023 Aug; 7(8):. PubMed ID: 37486965
[TBL] [Abstract] [Full Text] [Related]
7. MCL1 Inhibition Overcomes the Aggressiveness Features of Triple-Negative Breast Cancer MDA-MB-231 Cells.
Pratelli G; Carlisi D; Di Liberto D; Notaro A; Giuliano M; D'Anneo A; Lauricella M; Emanuele S; Calvaruso G; De Blasio A
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446326
[TBL] [Abstract] [Full Text] [Related]
8. Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line.
Hekmatshoar Y; Karadag Gurel A; Ozkan T; Rahbar Saadat Y; Koc A; Karabay AZ; Bozkurt S; Sunguroglu A
Adv Med Sci; 2023 Sep; 68(2):238-248. PubMed ID: 37421850
[TBL] [Abstract] [Full Text] [Related]
9. Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Chemotherapy in Acute Myeloid leukemia.
Qu S; Huang X; Guo X; Zheng Z; Wei T; Chen B
Drug Des Devel Ther; 2023; 17():1651-1663. PubMed ID: 37305402
[TBL] [Abstract] [Full Text] [Related]
10. Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6/JAK2/STAT3 signaling.
Lu J; Dong Q; Zhang S; Feng Y; Yang J; Zhao L
Cancer Sci; 2023 Aug; 114(8):3287-3300. PubMed ID: 37272257
[TBL] [Abstract] [Full Text] [Related]
11. Diallyl disulfide downregulating RhoGDI2 induces differentiation and inhibit invasion via the Rac1/Pak1/LIMK1 pathway in human leukemia HL-60 cells.
Hui T; Yiling J; Guangqun C; Ran L; Hui L; Lan Y; Jie H; Su Q
Environ Toxicol; 2023 May; 38(5):1063-1077. PubMed ID: 36793247
[TBL] [Abstract] [Full Text] [Related]
12. Metformin attenuates multiple myeloma cell proliferation and encourages apoptosis by suppressing METTL3-mediated m6A methylation of THRAP3, RBM25, and USP4.
Chen CJ; Huang JY; Huang JQ; Deng JY; Shangguan XH; Chen AZ; Chen LT; Wu WH
Cell Cycle; 2023 Apr; 22(8):986-1004. PubMed ID: 36762777
[TBL] [Abstract] [Full Text] [Related]
13. Clinical summary of pediatric acute lymphoblastic leukemia patients complicated with asparaginase-associated pancreatitis in SCCLG-ALL-2016 protocol.
Wang J; Jia WG; Yang LH; Kuang WY; Huang LB; Chen HQ; Wang LN; Zhou DH; Liao N
Hematology; 2023 Dec; 28(1):2171723. PubMed ID: 36752506
[TBL] [Abstract] [Full Text] [Related]
14. The role of BMI1 in endometrial cancer and other cancers.
Zhao Y; Yang W; Zheng K; Chen J; Jin X
Gene; 2023 Mar; 856():147129. PubMed ID: 36563713
[TBL] [Abstract] [Full Text] [Related]
15. Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis.
Tian Z; Tan Y; Lin X; Su M; Pan L; Lin L; Ou G; Chen Y
Transl Res; 2023 May; 255():66-76. PubMed ID: 36400307
[TBL] [Abstract] [Full Text] [Related]
16. Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia.
Liu Y; Song Y; Yin Q
Front Immunol; 2022; 13():962552. PubMed ID: 36059445
[TBL] [Abstract] [Full Text] [Related]
17. RNA
Tan B; Zhou K; Liu W; Prince E; Qing Y; Li Y; Han L; Qin X; Su R; Pokharel SP; Yang L; Zhao Z; Shen C; Li W; Chen Z; Zhang Z; Deng X; Small A; Wang K; Leung K; Chen CW; Shen B; Chen J
Theranostics; 2022; 12(13):5727-5743. PubMed ID: 35966596
[TBL] [Abstract] [Full Text] [Related]
18. A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors.
Dong J; Pervaiz W; Tayyab B; Li D; Kang L; Zhang H; Gong H; Ma X; Li J; Agboyibor C; Bi Y; Liu H
Eur J Med Chem; 2022 Oct; 240():114564. PubMed ID: 35820351
[TBL] [Abstract] [Full Text] [Related]
19. The bioengineered HALOA complex induces anoikis in chronic myeloid leukemia cells by targeting the BCR-ABL/Notch/Ikaros/Redox/Inflammation axis.
Singh V; Singh R; Mahdi AA; Tripathi AK
J Med Life; 2022 May; 15(5):606-616. PubMed ID: 35815090
[TBL] [Abstract] [Full Text] [Related]
20. Characterization of the impact of the
Abaji R; Roux V; Yssaad IR; Kalegari P; Gagné V; Gioia R; Ferbeyre G; Beauséjour C; Krajinovic M
Pharmacogenomics; 2022 May; 23(7):415-430. PubMed ID: 35485735
[No Abstract] [Full Text] [Related]
[Next]
